1 Min Read
Jan 9 (Reuters) - Cumberland Pharmaceuticals Inc :
* Cumberland pharmaceuticals and Clinigen enter exclusive U.S. commercialization agreement for Totect
* Preparations are now underway for U.S. launch of Totect later this year
* Under terms Cumberland granted an exclusive U.S. license,will manage marketing, promotion, distribution of Totect in U.S.
* Clinigen SP to continue to commercialize Dexrazoxane products, Savene, Cardioxane, in Europe, other territories outside U.S. Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)